Celadon Pharmaceuticals PLC Admission of Shares and Total Voting Rights
September 17 2024 - 4:28AM
RNS Regulatory News
RNS Number : 5064E
Celadon Pharmaceuticals PLC
17 September 2024
Celadon Pharmaceuticals
Plc
("Celadon" or the "Company"
or the "Group")
Admission of Shares and Total
Voting Rights
London, 17 September 2024 -
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical
company focused on the development, production and sale of
breakthrough cannabis-based medicines, is pleased to announce that
further to the announcement on 11 September 2024, application for
the admission of 2,625,000 new ordinary shares to trading on AIM
(the "Admission") has been made and 2,625,000
new ordinary shares were admitted to trading today.
The Company advises that on
Admission the Company's issued share capital will consist of
68,845,807 Ordinary Shares, with one voting right each. The Company
does not hold any shares in treasury. Therefore, the total number
of Ordinary Shares and voting rights in the Company will be
68,845,807. This figure may be used by shareholders in the Company
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
|
|
|
|
Celadon Pharmaceuticals Plc
|
|
|
James Short
Jonathan Turner
|
Via Sodali & Co
|
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and
Broker)
|
|
|
Bobbie Hilliam / Andrew
Potts
|
+44 (0)20 7523 8000
|
|
|
|
|
Global Investment Strategy UK Limited (Joint
Broker)
James
Sheehan
|
+44 (0)20 7048 9400
|
|
|
|
|
Sodali & Co
|
|
|
Elly Williamson / Sam Austrums /
Nick Johnson
|
+44 (0)20 7250 1446
|
|
|
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a
UK-based pharmaceutical company focused on the development,
production and sale of breakthrough cannabis-based medicines. Its
primary focus is on improving quality of life for chronic pain
sufferers, as well as exploring the potential of cannabis-based
medicines for other conditions such as autism. Its 100,000 sq. ft
UK facility is EU-GMP approved and comprises indoor hydroponic
cultivation, proprietary GMP extraction and an analytical and
R&D laboratory. Celadon's Home Office licence allows for the
commercial supply of its pharmaceutical-grade cannabis product. The
Group owns an approved clinical trial using cannabis-based
medicinal products to treat chronic pain in the UK. Celadon also
has a minority interest in early-stage biopharma Kingdom
Therapeutics, which is developing a licensed cannabinoid medicine
to treat children with Autism Spectrum Disorder.
For further information please visit
our website www.celadonpharma.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ALSQKOBBFBKKPCD
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Dec 2023 to Dec 2024
